<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients</dc:title><dc:creator>Fokter Dovnik,	Nina	(Avtor)
	</dc:creator><dc:creator>Takač,	Iztok	(Avtor)
	</dc:creator><dc:subject>node-negative breast cancer</dc:subject><dc:subject>adjuvant systemic treatment</dc:subject><dc:subject>survival</dc:subject><dc:subject>uPA/PAI-1</dc:subject><dc:subject>HER2 status</dc:subject><dc:description>Background: The association of HER2 status with urokinase plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1) levels raises the question whether uPA/PAI-1 level carries additional clinically relevant prognostic information independently from HER2 status. The aim of our study was to compare the prognostic value of uPA/PAI-1 level, HER2 status, and traditional prognostic factors for survival in node-negative breast cancer patients.

Patients and methods: A retrospective analysis of 858 node-negative breast cancer patients treated in Maribor University Clinical Center, Slovenia, in the years 2000-2009 was performed. Data were obtained from patient medical records. The median follow-up time was 100 months. Univariate and multivariate analyses of disease-free (DFS) and overall survival (OS) were performed using the Cox regression and the Cox proportional hazards model.

Results: In univariate analysis, age, tumor size, grade, lymphovascular invasion, HER2 status and UPA/PAI-1 level were associated with DFS, and age, tumor size, grade, and uPA/PAI-1 level were associated with OS. In the multivariate model, the most important determinants of DFS were age, estrogen receptor status and uPA/PAI-1 level, and the most important factors for OS were patient age and tumor grade. The HR for death from any cause in the multivariate model was 1.98 (95% CI 0.83-4.76) for patients with high uPA and/or PAI-1 compared to patients with both values low.

Conclusions: uPA/PAI-1 level clearly carries an independent prognostic value regardless of HER2 status in node-negative breast cancer and could be used in addition to HER2 and other markers to guide clinical decisions in this setting.</dc:description><dc:date>2017</dc:date><dc:date>2017-05-10 11:07:24</dc:date><dc:type>Znanstveno delo</dc:type><dc:identifier>65612</dc:identifier><dc:identifier>ISSN: 1581-3207</dc:identifier><dc:identifier>UDK: 618.19-006</dc:identifier><dc:identifier>OceCobissID: 784507</dc:identifier><dc:identifier>COBISS_ID: 5717567</dc:identifier><dc:identifier>DOI: 10.1515/raon-2016-0024</dc:identifier><dc:identifier>ISSN pri članku: 1581-3207</dc:identifier><dc:identifier>NUK URN: URN:SI:UM:DK:3AHMOAMK</dc:identifier><dc:language>sl</dc:language></metadata>
